Cite
HARVARD Citation
Vermeire, S. et al. (n.d.). DOP002 Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study. Journal of Crohn's and colitis. pp. S030-S031. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Vermeire, S. et al. (n.d.). DOP002 Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study. Journal of Crohn's and colitis. pp. S030-S031. [Online].